Congenital diaphragmatic hernias
Drug research and approvals for congenital diaphragmatic hernias: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 29 studies of congenital diaphragmatic hernias are recruiting on ClinicalTrials.gov, and Health Canada has authorized 0 drug trials for it since 2013.
- Recruiting worldwide: 29
- Trials authorized in Canada: 0
- FDA orphan approvals: 0
- EU medicines: 0
- Effect of Melatonin on Pulmonary Hypertension in Full Term NeonatesNCT07850934 · Not applicable · Ain Shams University · starts Jul 1, 2025
- Safety and Efficacy of Fetoscopic Endoluminal Tracheal Occlusion (FETO) in Congenital Diaphragmatic Hernia (CDH)NCT07577414 · Not applicable · Dr Erin Perrone · starts Jun 17, 2026
- Safety and Efficacy of FETO in CDH Phase IIINCT07187206 · Phase 3 · Children's Hospital Medical Center, Cincinnati · starts Sep 30, 2025
- Prospective Registry for Long-term Outcomes Following FETO in Severe Left and Right CDHNCT07166172 · Not applicable · Johns Hopkins University · starts Jun 23, 2025
- Safety and Efficacy of FETO in CDH: A Phase III TrialNCT06884423 · Not applicable · Holly L Hedrick, MD · starts Apr 7, 2025
- North American Fetal Therapy Network for Long-term Outcome Following Fetoscopic Endoluminal Tracheal Occlusion in…NCT06739356 · Not applicable · The University of Texas Health Science Center, Houston · starts Mar 4, 2025
- An Exploratory Physiological Study of Post-operative Recovery in Surgical Neonates and Dimethylarginine:Arginine LevelsNCT06731855 · Not reported · Liverpool Women's NHS Foundation Trust · starts Feb 5, 2024
- Physiological Umbilical Cord Clamping in Patients With Congenital Diaphragmatic Hernia. Clinical TrialNCT06408376 · Not applicable · Hospital JP Garrahan · starts Jun 14, 2022
- Improving Gastrointestinal Function In High-Risk Newborns By Stimulation Of The Enteric Nervous SystemNCT06057415 · Not applicable · Radboud University Medical Center · starts Jun 10, 2024
Phase 3 10
- Nitric oxideSoluble guanylate cyclase activator
- MacitentanEndothelin receptor, ET-A/ET-B antagonist
- NorepinephrineAdrenergic receptor agonist
- Gadobenate dimeglumineDiagnostic agent
- LiothyronineThyroid hormone receptor agonist
- AllopurinolXanthine dehydrogenase inhibitor
- GadopiclenolDiagnostic agent
- DopamineBeta-1 adrenergic receptor agonist
- DexamethasoneGlucocorticoid receptor agonist
- Mannitol
Phase 2 12 of 14
- DexmedetomidineAdrenergic receptor alpha-2 agonist
- MilrinonePhosphodiesterase 3A inhibitor
- BosentanEndothelin receptor, ET-A/ET-B antagonist
- Tryptophan
- TheophyllinePhosphodiesterase 4 inhibitor
- PhenoxybenzamineAdrenergic receptor alpha antagonist
- PalivizumabFusion glycoprotein F0 inhibitor
- SevofluraneGlycine receptor (alpha-1/beta) positive modulator
- VasopressinVasopressin receptor agonist
- MotavizumabFusion glycoprotein F0 inhibitor
- LevosimendanPhosphodiesterase 3 inhibitor
- Fibrinogen, humanFibrinogen exogenous protein
Phase 1 or earlier 3
- TopiramateCarbonic anhydrase II inhibitor
- Antithrombin iii human
- Autologous cord blood
How its trials ended
83 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 14 whose ending is known, 14% met their primary endpoint, 7% missed it and 79% stopped early.
- Ongoing3643%
- Completed, result not reported2328%
- Status unknown1012%
- Stopped: other or unclear67%
- Stopped: enrollment or feasibility34%
- Met its primary endpoint22%
- Missed its primary endpoint11%
- Stopped: lack of efficacy11%
- Stopped: sponsor or business decision11%
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA